Alzamend Neuro, Inc.

ALZN

$1.05

$-0.45 (-30.00%)

Closed

Topline Phase II data release sparks sell-the-news plunge in ALZN shares.

IndexN/A

Market Cap0.00B

Enterprise Value-0.00B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-0.29

P/SN/A

P/B0.60

P/C-0.34

EV/EBITDA0.36

EV/SalesN/A

EPS (ttm)-3.67

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.68M

Shs Outstand0.00B

Change-30.00%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Mar 2608:00AMAlzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions(prnewswire.com)

Mar 1608:00AMAlzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital(prnewswire.com)

Jan 1301:38AMAlzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?(defenseworld.net)

Nov 22

Insider Trading

View All

Insider

Type

Price

Value

Date

AULT MILTON C III

Sell

1.9K

$2.07

$4K

Dec 23, 25

Horne William B.

Sell

3.3K

$2.12

$7K

Dec 19, 25

McGrath Lynne Fahey

Sell

$2.29

$69

Oct 23, 25

AULT MILTON C III

Sell

20.4K

$2.32

$47K

Oct 9, 25

AULT MILTON C III

Sell

101.4K

$2.44

$247K

Oct 8, 25

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

CEO: Stephan JackmanEmployees: 4www.alzamend.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$50.74K	$50.74K	$23.07K	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-50.74K	$-50.74K	$-23.07K	N/A	N/A	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$4.45M	$9.89M	$14.85M	$12.32M	$4.95M	$4.42M	$5.01M	$898.00K
Operating Income	$-4.50M	$-9.94M	$-14.87M	$-12.32M	$-4.95M	$-4.42M	$-5.01M	$-898.00K
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-4.51M	$-9.95M	$-14.88M	$-12.36M	$-5.05M	$-4.41M	$-4.86M	$-932.00K
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-11.32	$-14.72	$-2.25	$-20.92	$-0.89	$-9.26	$-12.40	$-1.64
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Alzamend Neuro, Inc.

Insider Trading

Discover more